Atara Biotherapeutics Expects Cash Runway Into 2027, Enabling Key Pipeline Readouts
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics announced that it expects its cash runway to extend into 2027, which will support key pipeline readouts. The company plans to initiate a trial for ATA3219 in Systemic Lupus Erythematosus in the fourth quarter, with initial data expected by mid-2025.
August 12, 2024 | 9:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atara Biotherapeutics expects its cash runway to last into 2027, which will support key pipeline readouts. The company plans to initiate a trial for ATA3219 in Systemic Lupus Erythematosus in the fourth quarter, with initial data expected by mid-2025.
The extension of the cash runway into 2027 provides financial stability for Atara Biotherapeutics, which is crucial for ongoing and future R&D activities. The initiation of the ATA3219 trial in Q4 and expected data by mid-2025 are positive developments that could drive investor confidence and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100